Unknown

Dataset Information

0

Molecular modeling simulation studies reveal new potential inhibitors against HPV E6 protein.


ABSTRACT: High-risk strains of human papillomavirus (HPV) have been identified as the etiologic agent of some anogenital tract, head, and neck cancers. Although prophylactic HPV vaccines have been approved; it is still necessary a drug-based treatment against the infection and its oncogenic effects. The E6 oncoprotein is one of the most studied therapeutic targets of HPV, it has been identified as a key factor in cell immortalization and tumor progression in HPV-positive cells. E6 can promote the degradation of p53, a tumor suppressor protein, through the interaction with the cellular ubiquitin ligase E6AP. Therefore, preventing the formation of the E6-E6AP complex is one of the main strategies to inhibit the viability and proliferation of infected cells. Herein, we propose an in silico pipeline to identify small-molecule inhibitors of the E6-E6AP interaction. Virtual screening was carried out by predicting the ADME properties of the molecules and performing ensemble-based docking simulations to E6 protein followed by binding free energy estimation through MM/PB(GB)SA methods. Finally, the top-three compounds were selected, and their stability in the E6 docked complex and their effect in the inhibition of the E6-E6AP interaction was corroborated by molecular dynamics simulation. Therefore, this pipeline and the identified molecules represent a new starting point in the development of anti-HPV drugs.

SUBMITTER: Ricci-Lopez J 

PROVIDER: S-EPMC6420176 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Molecular modeling simulation studies reveal new potential inhibitors against HPV E6 protein.

Ricci-López Joel J   Vidal-Limon Abraham A   Zunñiga Matías M   Jimènez Verónica A VA   Alderete Joel B JB   Brizuela Carlos A CA   Aguila Sergio S  

PloS one 20190315 3


High-risk strains of human papillomavirus (HPV) have been identified as the etiologic agent of some anogenital tract, head, and neck cancers. Although prophylactic HPV vaccines have been approved; it is still necessary a drug-based treatment against the infection and its oncogenic effects. The E6 oncoprotein is one of the most studied therapeutic targets of HPV, it has been identified as a key factor in cell immortalization and tumor progression in HPV-positive cells. E6 can promote the degradat  ...[more]

Similar Datasets

| S-EPMC4574123 | biostudies-other
| S-EPMC9122669 | biostudies-literature
| S-EPMC3651465 | biostudies-other
| S-EPMC7332866 | biostudies-literature
| S-EPMC5065998 | biostudies-literature
2024-08-25 | GSE274812 | GEO
| S-EPMC4099350 | biostudies-literature
| S-EPMC2582798 | biostudies-literature
| S-EPMC7382397 | biostudies-literature
| 2177506 | ecrin-mdr-crc